T cell engagers connect patient T cells directly to cancer cells, creating an artificial immune synapse that triggers potent tumor killing. No cell engineering required - just a biologic drug that redirects immunity.
Multiple formats for redirecting T cell immunity against cancer
Amgen's pioneering format linking two scFvs. Blinatumomab (Blincyto) was first-to-market for r/r B-ALL. Continuous IV infusion required due to short half-life.
Fc-fusion BiTEs like Tarlatamab achieve weekly or biweekly dosing. Improved pharmacokinetics enable outpatient administration and better patient convenience.
Targeting multiple myeloma's BCMA antigen. Teclistamab, elranatamab, and GPRC5D engagers showing deep responses in heavily pretreated patients.
HER2, EGFR, and other targets bringing T cell engagers to solid tumors. Managing on-target/off-tumor toxicity is key challenge for next-generation designs.
Trispecifics adding NK cell engagement or tumor specificity. DARTs, TriTACs, and other scaffolds optimizing avidity, half-life, and safety profiles.
Protease-activated or pH-sensitive engagers that activate only in tumor microenvironment. Reducing systemic T cell activation for improved therapeutic index.
Companies advancing bispecific immunotherapy
| Company | Platform | Approved Products | Key Targets |
|---|---|---|---|
| Amgen | BiTE, Half-life Extended BiTE | Blincyto, Imdelltra | CD19, DLL3, BCMA |
| Johnson & Johnson | DuoBody | Tecvayli, Talvey | BCMA, GPRC5D |
| Pfizer | Bispecific antibody | Elrexfio | BCMA |
| Roche/Genentech | CrossMAb | Lunsumio, Columvi | CD20 |
| AbbVie | DuoBody (licensed) | Epkinly | CD20 |
| Regeneron | VelociSuite | Multiple Phase III | Various |
| MacroGenics | DART | Tebotelimab (Ph3) | HER2, PD-1/LAG-3 |
| Harpoon Therapeutics | TriTAC | Clinical stage | BCMA, DLL3, MSLN |
TcellEngager.com - Premium domain for the bispecific antibody space. Ideal for platforms, education, or therapeutic development.
Contact for Pricing